Associated Papers
Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics.
Kohlmann W et al.
Jco Precision Oncology, 2024
The Prevalence of CHEK1 and CHEK2 Mutations in Prostate Cancer: a Retrospective Cohort Study.
Alorjani M et al.
Medical Archives (sarajevo, Bosnia and Herzegovina), 2023
Concurrent loss of MLH1, PMS2 and MSH6 immunoexpression in digestive system cancers indicating a widespread dysregulation in DNA repair processes.
Reitsam NG et al.
Frontiers in Oncology, 2022
Diagnostic value of partial exome sequencing in developmental disorders.
Gieldon L et al.
Plos One, 2018
30091983 (PubMed )
Supplement: pone.0201041.s004.xlsx › Tabelle1
Case report of a Li-Fraumeni syndrome-like phenotype with a de novo mutation in CHEK2.
Zhuang X et al.
Medicine, 2016
Evolutionary analysis of the highly dynamic CHEK2 duplicon in anthropoids.
Münch C et al.
Bmc Evolutionary Biology, 2008
Role of CHK2 in cancer development.
Perona R et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008
CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?
Antoni L et al.
Nature Reviews. Cancer, 2007
Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.
van Puijenbroek M et al.
The Journal of Pathology, 2005
Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome.
Sodha N et al.
Human Mutation, 2002
A robust method for detecting CHK2/RAD53 mutations in genomic DNA.
Sodha N et al.
Human Mutation, 2002
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.
Lee SB et al.
Cancer Research, 2001
Select a paper to view details